Brazikumab

Brazikumab
Monoclonal antibody
Type	Whole antibody
Source	Human
Target	IL23
Clinical data
Other names	MEDI2070
ATC code	none;
Identifiers
CAS Number	1610353-18-8;
ChemSpider	none;
UNII	50EI9G8Q6U;
KEGG	D10912;
Chemical and physical data
Formula	C6410H9830N1718O2016S50
Molar mass	144820.16 g·mol−1

Brazikumab (INN; development code MEDI2070) is a human monoclonal antibody designed for the treatment of Crohn's disease.^[1]^[2] It targets IL-23.^[3]

This drug was developed by MedImmune.

References

^ Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association
^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).
^ Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Brazikumab, American Medical Association

[2] World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 115" (PDF). WHO Drug Information. 30 (2).

[pmid31760827-3] Hanžel J, D'Haens GR (April 2020). "Anti-interleukin-23 agents for the treatment of ulcerative colitis". Expert Opinion on Biological Therapy. 20 (4): 399–406. doi:10.1080/14712598.2020.1697227. PMID 31760827.

[1]

[2]

[3]